Assessment of atypical DNA intercalating agents in biological and in silico systems

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 623, Issue 1-2, 2007, Pages 72-82

  Snyder, Ronald D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chinese hamster V79 cells; DNA intercalation; DNA topoisomerase II; In silico

Indexed keywords

ACRIDINE ORANGE; AMINOACRIDINE; ASTEMIZOLE; BENZO[A]PYRENE; BLEOMYCIN; CHLOROQUINE; CHLORPHENIRAMINE; CHLORPROMAZINE; CICLOPIROX; CLASTOGEN; CLOFIBRATE; CYPROHEPTADINE; DAIDZEIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ENALAPRIL; GALANGIN; GYRASE INHIBITOR; IMIPRAMINE; INTERCALATING AGENT; METHAPYRILENE; MEVINOLIN; NARINGENIN; PHENOTHIAZINE; PROFLAVINE; STILBENE; TAMOXIFEN; TAXIFOLIN; TERFENADINE; UNINDEXED DRUG;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DNA BINDING; DRUG STRUCTURE; FRAMESHIFT MUTATION; GENOTOXICITY; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ANIMALS; CELL LINE; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; ELECTROSTATICS; ENZYME INHIBITORS; INTERCALATING AGENTS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION;

BACTERIA (MICROORGANISMS); CRICETULUS GRISEUS; MAMMALIA;

EID: 34548456830     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.03.006     Document Type: Article

References (40)

1. Snyder R.D. A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Mutat. Res. 411 (1998) 235-248
2. Strekowski L., Strekowska A., Watson R.A., Tanious F.A., Nguyen L.T., and Wilson W.D. Amplification of bleomycin-mediated degradation of DNA. J. Med. Chem. 30 (1987) 1415-1420
3. Strekowski L., Mokrosz J.L., Tanious F.A., Watson R.A., Harden D., Mokrosz M., Edwards W.D., and Wilson W.D. Molecular basis for bleomycin amplification: conformational and stereoelectronic effects in unfused amplifiers. J. Med. Chem. 31 (1988) 1231-1240
4. Wilson W.D., Strekowski L., Tanious F.A., Watson R.A., Mokrosz J.L., Strekowska A., Webster G.D., and Neidle S. Binding of unfused aromatic cations to DNA. The influence of molecular twist on intercalation. J. Am. Chem. Soc. 110 (1988) 8292-8299
5. Wilson W.D., Tanious F.A., Barton H.J., Wydra R.L., Jones R.L., Boykin D.W., and Strekowska L. The interaction of unfused polyaromatic heterocycles with DNA: intercalation, groove-binding and bleomycin amplification. Anticancer Drug Des. 5 (1990) 31-42
6. Snyder R.D., and Strekowski J. Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds. Mutat. Res. 444 (1999) 181-192
7. Snyder R.D., and Diehl M.S. The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents. Mutagenesis 15 (2000) 203-205
8. Hendry L.B., Chu C.K., Rosser M.L., Copland J.A., Wood J.C., and Mahesh V.B. Design of novel antiestrogens. J. Steroid Biochem. Mol. Biol. 49 (1994) 269-280
9. Hendry L.B., Roach L.W., and Mahesh V.B. Multidimensional screening and design of pharmaceuticals by using endocrine pharmacophores. Steroids 64 (1999) 570-575
10. Hendry L.B., Bransome Jr. E.D., and Mahesh V.B. The ligand insertion hypothesis in the genomic action of steroid hormones. J. Steroid Biochem. Mol. Biol. 65 (1998) 75-89
11. Mahesh V.B., Roach L.W., Cannady W.E., Ogle T.F., Brann D.W., Bransome Jr. E.D., and Hendry L.B. Gene-based pharmacophores for drug design. Med. Chem. 10 (2001) 440-455
12. Porterfield S.P., and Hendry L.B. Impact of PCBs on thyroid hormone directed brain development. Tox. Indust. Hlth. J. 14 (1998) 103-120
13. Snyder R.D., Ewing D.E., and Hendry L.B. Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ. Mol. Mutagen. 44 (2004) 163-173
14. Snyder R.D., Mcnulty J., Zairov G., Ewing D.E., and Hendry L.B. The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutat. Res. 578 (2005) 88-99
15. W.A. Denny, Acridine-4-carboxamides and the concept of minimal DNA intercalators. Chapter 18 in: M. Demeunynck, C. Bailly, W.D. Wilson (Eds.), "DNA and RNA binders: From small molecules to drugs-Volume 2". Wiley-VCH, Weinheim, 00. 482-502 (2002).
16. Snyder R.D., and Brown J.E. Evidence for and role of the dimethylamino group in tamoxifen DNA intercalation in intact Chinese hamster V79 cells. Drug Chem. Toxicol. 25 (2002) 473-479
17. Garbett N.C., Hammond N.B., and Graves D.E. Influence of the amino substituents in the interaction of ethidium bromide with DNA. Biophys. J. 87 (2004) 3974-3981
18. Snyder R.D., and Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488 (2001) 151-169
19. Snyder R.D., Pearl G.S., Mandakas G., Choy W.N., Goodsaid F., and Rosenblum I.Y. Assessment of the sensitivity of the computational programs DEREK, TOPKAT and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ. Mol. Mutagen. 43 (2004) 143-158
20. Snyder R.D., and Smith M.D. Computational prediction of genotoxicity: Room for improvement. Drug Discov. Today: BioInsilico 10 (2005) 1119-1124
21. Denny W.A. DNA intercalating ligands as anticancer drugs: Prospect for future design. Anticancer Drug. Des. 4 (1989) 241-263
22. Albertini S., Chetelat A., Miller B., Muster W., Pudjadas E., Strobel R., and Gocke E. Genotoxicity of 17 gyrase and four mammalian topoisomerase II poisons in prokaryotic and eukaryotic test systems. Mutagenesis 10 (1995) 343-351
23. Snyder R.D., and Gillies P.J. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Mol. Mutagen. 40 (2002) 266-276
24. Snyder R.D., Ewing D., and Hendry L.B. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat. Res. 609 (2006) 47-59
25. Liu G.L., Yin Y., Kunchakarra S., Mukherjee B., Gerion D., Jett S.D., Bear D.G., Gray J.W., Alivasatos A.P., Lee L.P., and Chen F. A nanoplasmonic molecular ruler for measuring nuclease activity and DNA footprinting. Nat. Nanotechnology 1 (2006) 47-52
26. Chaires J.B. A thermodynamic signature for drug-DNA binding mode. Arch. Biochem. Biophys. 453 (2006) 24-29
27. Zhang A., Lyu Y.L., Lin C.-P., Zhou N., Azarova A.M., Wood L.M., and Liu L.F. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J. Biol. Chem. 281 (2006) 35997-36003
28. Baguley B.C., Wakelin L.P.G., Jacintho J.D., and Kovacic P. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?. Curr. Med. Chem. 10 (2003) 2643-2649
29. Jensen P.B., and Sehested M. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem. Pharmacol. 54 (1997) 755-759
30. Jensen P.B., Jensen P.S., Demant E.J.F., Friche E., Sorensen B.S., Sehested M., Wassermann K., Vindiloev L., Westergaard O., and Hansen H.H. Antagonistic effect of aclarubicin in daunorubicin-induced cytotoxicity in human small cell lung cancer cells; relationship to DNA integrity and topoisomerase II. Cancer Res. 51 (1991) 5093-5099
31. Osheroff N., Shelton E.R., and Brutlag D.L. DNA topoisomerase II from Drosophila melanogaster; relaxation of supercoiled DNA. J. Biol. Chem. 258 (1983) 9536-9543
32. Snyder R.D. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical induced clastogenicity in Chinese hamster V79 cells. Environ. Mol. Mutagen. 35 (2000) 13-21
33. Ju R., Mao Y., Glick M.J., Muller M.T., and Snyder R.D. Catalytic inhibition of DNA topoisomerase II by sodium azide. Toxicol. Lett. 121 (2001) 119-126
34. Snyder R.D. Evidence from studies with intact mammalian cells that merbarone and bis(Dioxopiperazine)s are topoisomerase II poisons. Drug Chem. Toxicol. 26 (2003) 15-22
35. Snyder R.D., and Gillies P.J. Reduction of genistein clastogenicity in Chinese hamster V79 cells by daidzein and other flavonoids. Food Chem. Toxicol. 41 (2003) 1291-1298
36. Snyder R.D., and Arnone M.R. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat. Res. 503 (2002) 21-35
37. Jensen P.B., Sorensen B.S., Sehested M., Grue P., Demant E.J.F., and Hansen H.H. Targeting the cytotoxicity of topoisomerase II-directed epipdophyllotoxins to tumor cells in acidic environments. Cancer Res. 54 (1994) 2959-2963
38. Von Bardeleben R., Dunkern T., Kaina B., and Fritz G. The HMG CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int. J. Mol. Med. 10 (2002) 473-479
39. Feleszko W., Mlynarczuk I., Balkowiec-Iskra E.Z., Czajka A., Switraj T., and Stoklosa T. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. 6 (2000) 2052-2055
40. Damrot J., Nubel T., Epe B., Roos W.P., Kaina B., and Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 149 (2006) 988-997